These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6837595)

  • 1. Prolactinomas as part of the multiple endocrine neoplastic syndrome type 1.
    Hershon KS; Kelly WA; Shaw CM; Schwartz R; Bierman EL
    Am J Med; 1983 Apr; 74(4):713-20. PubMed ID: 6837595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromocriptine and pituitary disorders.
    Kellett J; Friesen HG
    Ann Intern Med; 1979 Jun; 90(6):980-2. PubMed ID: 443696
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperprolactinemia. Morphologic and clinical considerations.
    Ezrin C; Kovacs K; Horvath E
    Med Clin North Am; 1978 Mar; 62(2):393-408. PubMed ID: 205742
    [No Abstract]   [Full Text] [Related]  

  • 4. Regression of pituitary prolactinoma after treatment with bromocriptine.
    Landolt AM; Wüthrich R; Fellmann H
    Lancet; 1979 May; 1(8125):1082-3. PubMed ID: 86800
    [No Abstract]   [Full Text] [Related]  

  • 5. Bromocriptine in pituitary tumours.
    Corenblum B
    Lancet; 1978 Oct; 2(8093):786. PubMed ID: 80708
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors.
    Farid NR; Buehler S; Russell NA; Maroun FB; Allerdice P; Smyth HS
    Am J Med; 1980 Dec; 69(6):874-80. PubMed ID: 6108714
    [No Abstract]   [Full Text] [Related]  

  • 7. Giant invasive prolactinomas.
    Murphy FY; Vesely DL; Jordan RM; Flanigan S; Kohler PO
    Am J Med; 1987 Nov; 83(5):995-1002. PubMed ID: 3674103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas.
    Hancock KW; Scott JS; Lamb JT; Gibson RM; Chapman C
    Br Med J (Clin Res Ed); 1985 Jan; 290(6462):117-8. PubMed ID: 3917709
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
    Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
    J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The classification and molecular biology of pituitary adenomas.
    Thapar K; Kovacs K; Laws ER
    Adv Tech Stand Neurosurg; 1995; 22():3-53. PubMed ID: 7495421
    [No Abstract]   [Full Text] [Related]  

  • 11. Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas?
    Landolt AM; Keller PJ; Froesch ER; Mueller J
    Lancet; 1982 Sep; 2(8299):657-8. PubMed ID: 6125789
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of prolactinomas--1986.
    Tan SL; Jacobs HS
    Br J Obstet Gynaecol; 1986 Oct; 93(10):1025-9. PubMed ID: 3790461
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy.
    Wass JA; Moult PJ; Thorner MO; Dacie JE; Charlesworth M; Jones AE; Besser GM
    Lancet; 1979 Jul; 2(8133):66-9. PubMed ID: 87966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid rhinorrhea caused by bromocriptine therapy of prolactinoma.
    Holness RO; Shlossberg AH; Heffernan LP
    Neurology; 1984 Jan; 34(1):111-3. PubMed ID: 6537833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactinomas.
    Grossman A; Besser GM
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):182-4. PubMed ID: 3917745
    [No Abstract]   [Full Text] [Related]  

  • 16. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tests of prolactin secretion in diagnosis of prolactinomas.
    Cowden EA; Ratcliffe JG; Thomson JA; Macpherson P; Doyle D; Teasdale GM
    Lancet; 1979 Jun; 1(8127):1155-8. PubMed ID: 86882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinomas and the multiple endocrine adenomatosis type-1 complex.
    Goldman M; Holub D
    Ann Intern Med; 1979 Nov; 91(5):791-2. PubMed ID: 40498
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy].
    Brabant G; Brennecke I; Herrmann H; Friedrich H; Wagner TO; von zur Mühlen A; Hesch RD
    Dtsch Med Wochenschr; 1985 Oct; 110(41):1564-7. PubMed ID: 4042883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: special reference to changes in secretory granules by stereological analysis].
    Saitoh Y; Koizumi K; Arita N; Hayakawa T; Aono T; Matsumoto K; Mogami H; Mori H
    No To Shinkei; 1987 Apr; 39(4):347-54. PubMed ID: 3593602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.